**Mean Weight Change from Baseline at Week 48 and Week 96 by Sex and Race**

|  | Doravirine Group | Darunavir Group | Efavirenz Group |
| --- | --- | --- | --- |
|  | n | BaselineMean | Mean Change95% CI | n | BaselineMean | Mean Change95% CI | n | BaselineMean | Mean Change95% CI |
| **Week 48** |
| Overall | 751 | 74.8 | 1.7 (1.4, 2.1) | 316 | 75.8 | 1.4 (0.6, 2.1) | 402 | 74.4 | 0.6 (-0.1, 1.2) |
| Male | 637 | 75.4 | 1.6 (1.2, 2.0) | 274 | 76.9 | 1.1 (0.3, 1.9) | 353 | 75.1 | 0.4 (-0.4, 1.1) |
| Female | 114 | 71.6 | 2.4 (1.3, 3.5) | 42 | 68.4 | 3.2 (0.7, 5.7) | 49 | 69.3 | 2.0 (0.1, 3.9) |
|  Female, Black | 50 | 75.2 | 4.3 (2.3, 6.4) | 12 | 73.9 | 3.5 (-0.4, 7.4) | 23 | 77.5 | 3.0 (-0.8, 6.8) |
|  Female, Non-Black | 64 | 68.8 | 0.9 (-0.2, 2.0) | 30 | 66.2 | 3.0 (-0.2, 6.3) | 26 | 62.0 | 1.1 (-0.5, 2.7) |
| Black | 136 | 75.8 | 3.4 (2.2, 4.6) | 63 | 78.8 | 3.4 (1.5, 5.3) | 66 | 80.2 | 1.5 (-0.5, 3.5) |
| Non-Black | 615 | 74.6 | 1.4 (1.0, 1.7) | 253 | 75.0 | 0.8 (0.0, 1.7) | 336 | 73.2 | 0.4 (-0.4, 1.1) |
| **Week 96** |
| Overall | 677 | 74.9 | 2.4 (1.9, 2.8) | 268 | 75.7 | 1.8 (0.8, 2.7) | 362 | 74.5 | 1.6 (0.9, 2.3) |
| Male | 575 | 75.6 | 2.2 (1.7, 2.7) | 236 | 76.8 | 1.6 (0.6, 2.6) | 316 | 75.2 | 1.4 (0.7, 2.1) |
| Female | 102 | 71.0 | 3.2 (1.9, 4.5) | 32 | 67.7 | 2.9 (0.1, 5.8) | 46 | 69.8 | 2.8 (0.6, 5.1) |
|  Female, Black | 43 | 74.9 | 3.8 (1.4, 6.2) | 10 | 73.2 | 1.7 (-1.5, 5.0) | 21 | 79.6 | 3.3 (-1.1, 7.7) |
|  Female, Non-Black | 59 | 68.3 | 2.8 (1.4, 4.1) | 22 | 65.1 | 3.5 (-0.5, 7.5) | 25 | 61.6 | 2.4 (0.1, 4.7) |
| Black | 113 | 75.8 | 4.5 (2.9, 6.1) | 52 | 78.0 | 2.8 (0.4, 5.2) | 53 | 81.9 | 2.2 (-0.3, 4.6) |
| Non-Black | 564 | 74.8 | 1.9 (1.5, 2.4) | 216 | 75.1 | 1.5 (0.5, 2.6) | 309 | 73.2 | 1.5 (0.8, 2.2) |
| n=Number of subjects included in the analysis. |